随着细胞生物学、细胞免疫学及分子遗传学的进展,CLL预后指标除了年龄、疾病分期(Rai/Biet分期)、外周血淋巴细胞计数、免疫表型等,还增加了细胞遗传学异常及其他血清学标志物,此外也涌现出一系列新型药物用于CLL的治疗。在刚结束的美国血液学会(ASH)年会上,组委会特别设计了“How I Treat: Bringing Science to Clinical...
Coffee and Collaboration in ASH Central (for in-person participants) How I Treat: Bringing Science to Clinical Dilemmas (for in-person participants) Meet the Scientist (for in-person participants) 9:00A.M - 9:30A.M Coff...
在之前的 CLL 随 机对照研究中,加用蒽环类药物未能被证实可使有 效率或 PFS 提高,但确定将增加药物毒性.对于 TP53 缺失的患者,阿仑单抗已成为其主要的治疗 方法,并可通过一项患者药品取得计划治疗该类病 例,尽管此药已不被许可用于 CLL 的治疗 .[28] 最 近发现,B 细胞受体(BCR)抑制剂(依鲁替尼和 艾代...
李智慧,北京高博博仁医院 278Gpibα Caar-T Cells Induce Autoreactive B Cells Elimination to Treat Immune Thrombocytopenia 梅恒,华中科技大学同济医学院附属协和医院 279Iguratimod Regulates CD4+ T-Cell Homeostasis and Function By Restoring PINK1/Parkin-Mediated Mitophagy in Immune Thrombocytopenia Yuxiu Chen,...
data analysis. But with some precedent in other studies, we used a 12-month washout period. So patients had to have not had any other prescriptions for their CLL for 12 months before that 2019 landmark where we started the analysis. And that’s how we identified first-line–treated ...
“We don’t even know how long the remissions last. So this is really life changing for these patients,” he said during a news briefing. Talquetamab is being developed by Janssen, which paid for the study.As the investigators explained in the NEJM article, the explosion of treatment ...
Based on the patient population explored in the study, should you treat younger patients differently from older patients? I think that the decision of [how] to treat is certainly still influenced by the age of the patient; it’s also, of course, influenced by the bi...
Presentations support Calquence efficacy and tolerability with long-term follow-up in mantle cell lymphoma and pooled safety data in chronic lymphocytic leukaemia Emerging pipeline shows promise with novel targets and mechanisms to treat resistant an
“The next step is, how can we better combine this agent with other standard treatments? How can we give it more post transplant to reduce the risk of relapse?” Giving it to patients in earlier lines of care could prove critical; in response to a question, Aldoss said patients who had...
2234 - How Much Have Post-Transplant Outcomes Improved Since 2000 for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia in First Remission? a Study from the EBMT Acute Leukemia Working Party Abou Mourad, Y. 1482 - Improvement in Survival of Patients with FLT3 Mutated Acute Myeloid ...